The present invention relates to tablet,
capsule and
ampoule formulations for oral and / or injectable use, said formulations comprising beta-D-
mannuronic acid or alpha-L-
guluronic acid or a mixture of beta-D-
mannuronic acid and alpha-L-
guluronic acid, their oligomers, or their pharmaceutically acceptable salts, the total amount of [beta]-D-
mannuronic acid or [alpha]-L-
guluronic acid or mixtures thereof, oligomers thereof, or pharmaceutically acceptable salts thereof is from 10% to 99.999% by weight, based on the total weight of the tablet or
capsule formulation, or from 20% to 60% by weight, based on the total weight of the
ampoule formulation; the tablet,
capsule or
ampoule formulation further comprises
caffeic acid or a salt thereof, for example in
powder form, in an amount preferably from 0.001 wt% to 1 wt%, more preferably from 0.01 wt% to 0.5 wt%, more preferably from 0.05 wt% to 0.3 wt%, based on the total weight of the tablet, capsule or ampoule formulation. Furthermore, the present invention relates to the oral and / or injectable use of tablet, capsule and ampoule formulations, preferably as supplements or medicaments, for use in methods for the treatment of neurodegenerative diseases, inflammatory responses, pain,
cancer, aging, diabetes and / or heart diseases, as well as to methods of preparing such formulations.